Addiction

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

MIAMI, FL / ACCESSWIRE / September 11, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing...

As Research into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront – Tonix Targets it with FDA-Fast Track-Designated TNX-102 SL

CHATHAM, NJ / ACCESSWIRE / September 4, 2024 / This post was written and published as a collaboration between the...

error: Content is protected !!